SCHEMBL2012795

SCHEMBL2012795

O=C(c1ccccc1)c1cc(F)cc(F)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.68
CNR2 P34972 2/20 0.68
ALDH1A1 P00352 1/20 0.64
ATM Q13315 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
SRD5A2 P31213 1/20 0.54
CES1 P23141 3/20 0.52
CES2 O00748 2/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
PBRM1 Q86U86 1/20 0.50
GABRA1 P14867 1/20 0.48
GABRB1 P18505 1/20 0.48
LMNA P02545 2/20 0.47
ALPG P10696 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
RAB9A P51151 2/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31052951 0.95 ATM (0.67) CNR1CNR2ALDH1A1ATMTDP1
SCHEMBL17064697 0.86 PBRM1 (0.61) CNR1CNR2ALDH1A1ATMTDP1
SCHEMBL28723978 0.86 CNR2 (0.58) CNR1CNR2ALDH1A1ATMTDP1
SCHEMBL4470662 0.85 CES2 (0.68) CNR1CNR2CES1CES2PARP1
SCHEMBL3834026 0.84 ATM (0.71) ALDH1A1ATMTDP1L3MBTL1SRD5A2
SCHEMBL29623677 0.84 ATM (0.71) ALDH1A1ATMTDP1L3MBTL1SRD5A2
SCHEMBL1069077 0.84 LTA4H (0.59) CNR1CNR2ALDH1A1ATMCES1
SCHEMBL13284137 0.83 CNR1 (0.51) CNR1CNR2ALDH1A1ATMTDP1
SCHEMBL3349765 0.83 ATM (0.84) CNR1CNR2ALDH1A1ATMTDP1
SCHEMBL133982 0.83 ATM (0.84) CNR1CNR2ALDH1A1ATMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119926191-B Conjugated microporous organic solvent-resistant nanofiltration composite membrane and preparation method and application thereof 中山大学 2025-06-13 CN claimed
CN-119926191-A Conjugated microporous organic solvent-resistant nanofiltration composite membrane and preparation method and application thereof 中山大学 2025-05-06 CN claimed
CN-114950159-B Preparation method of aromatic polymer separation membrane based on super acid catalysis 南京工业大学 2023-06-06 CN claimed
CN-114950159-A Preparation method of aromatic polymer separation membrane based on super-acid catalysis preparation 南京工业大学 2022-08-30 CN claimed
CN-119926191-B Conjugated microporous organic solvent-resistant nanofiltration composite membrane and preparation method and application thereof 中山大学 2025-06-13 CN disclosed
CN-119926191-A Conjugated microporous organic solvent-resistant nanofiltration composite membrane and preparation method and application thereof 中山大学 2025-05-06 CN disclosed
CN-114950159-B Preparation method of aromatic polymer separation membrane based on super acid catalysis 南京工业大学 2023-06-06 CN disclosed
CN-114950159-A Preparation method of aromatic polymer separation membrane based on super-acid catalysis preparation 南京工业大学 2022-08-30 CN disclosed
US-9663476-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2017-05-30 US disclosed
EP-2947067-A1 Glycine transporter-1 inhibitors Amgen, Inc (US) 2015-11-25 EP disclosed
US-20150307457-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2015-10-29 US disclosed
US-8735383-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2014-05-27 US disclosed
EP-0788497-B1 BISARYLCARBINOL DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA INC (CA) 2001-05-23 EP disclosed
EP-0788490-B1 BISARYLCARBINOL CINNAMIC ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA INC (CA) 2000-07-05 EP disclosed
EP-0788497-A1 BISARYLCARBINOL DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA INC. (CA) 1997-08-13 EP disclosed
EP-0788490-A1 BISARYLCARBINOL CINNAMIC ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA INC. (CA) 1997-08-13 EP disclosed
US-5552437-A ANTIASTHMATIC, ANTIALLERGIC, ANTIINFLAMMATORY, AND CYTOPROTECTIVE AGENTS MERCK FROSST CANADA, INC. (CA) 1996-09-03 US disclosed
US-5527827-A ANTIASTHMATIC, ANTIALLERGIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS MERCK FROSST CANADA, INC. (CA) 1996-06-18 US disclosed
WO-1996013491-A1 BISARYLCARBINOL CINNAMIC ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA INC. (CA) 1996-05-09 WO disclosed
WO-1996013500-A1 BISARYLCARBINOL DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA INC. (CA) 1996-05-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307457-A1 GLYCINE TRANSPORTER-1 INHIBITORS SLC18A2, SLC7A11, SLC6A5 CNR1 958/4885CNR2 1604/4885ALDH1A1 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.